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T cell acute lymphoblastic leukemia (T-ALL) is caused by mutations affecting cell survival, proliferation, and
differentiation. In addition to requiring these mutations, Passaro and colleagues and Pitt and colleagues in
this issue of Cancer Cell demonstrate that T-ALL initiating cells residing in bone marrow depend on the
CXCR4/CXCL12 signaling axis for disease maintenance and progression.The hematopoietic stem cell niche is
a specific microenvironment that is
required for the maintenance of hemato-
poietic stem cells and the proper develop-
ment of hematopoietic progenitor cells. In
adults, the major hematopoietic stem cell
niche is located in the bone marrow,
where hematopoietic stem cells are found
adjacent to sinusoids and other blood
vessels (Morrison and Scadden, 2014).
There, endothelial cells andmesenchymal
stromal cells produce essential factors,
including high levels of SCF and
CXCL12, to promote and support he-
matopoietic stem cell maintenance.
Osteoblasts play only an indirect role
for the stem cell niche but have been
shown to be essential for the develop-
ment of lymphoid progenitors where,
again, the production of CXCL12 seems
to be important (Morrison and Scadden,
2014).
CXCL12 (also known as SDF1) is a che-
mokine that binds to the heterotrimeric
G protein-coupled receptor CXCR4 and
plays an important role in the migration
of various cell types, including migration
of immune cells to the sites of inflam-
mation (Karpova and Bonig, 2015). The
essential role of CXCL12/CXCR4 in
hematopoietic stem cell maintenance
within the bone marrow is highlighted
by genetic ablation of CXCL12 (in stroma)
or CXCR4 (in hematopoietic stem
cells), resulting in hematopoietic stem
cell depletion, and by antagonism of
CXCL12/CXCR4, leading to hematopoiet-
ic stem cell mobilization out of the
bone marrow into the peripheral blood
(Karpova and Bonig, 2015; Morrison and
Scadden, 2014). The CXCR4 antagonist
AMD3100 (plerixafor) has been approved
by the United States Food and Drug
Administration and the European Medi-cines Agency for hematopoietic stem
cell mobilization, and other more potent
CXCR4 antagonists are under investiga-
tion (Karpova and Bonig, 2015).
Evidence now indicates that the
CXCL12/CXCR4 signaling axis also plays
a role in cancer biology. In solid tumors,
expression of CXCR4 has been detected
in over 20 tumor types, making it one
of the most frequent chemokine recep-
tors overexpressed in malignancy. The
CXCL12/CXCR4 signaling axis is regu-
lated by various oncogenic pathways
and correlates with metastasis and prog-
nosis, lending support to the idea that
CXCR4 antagonists could be used as a
new therapeutic strategy (Guo et al.,
2015; Kuo et al., 2014). Indeed, several
studies are investigating the anti-cancer
effects of blocking CXCR4 or CXCL12
in combination with chemotherapy or
other current cancer therapies (Guo
et al., 2015). The CXCL12/CXCR4 inter-
action has also been found to be impor-
tant in hematolological malignancies,
such as acute myeloid leukemia and
B cell acute lymphoblastic leukemia
(Rombouts et al., 2004; Patel et al.,
2014). Now, the work by Pitt et al.
(2015) and Passaro et al. (2015) in this
issue of Cancer Cell extends these find-
ings by showing the importance of
CXCL12/CXCR4 signaling in the mainte-
nance and progression of T-ALL.
Pitt et al. (2015) used in vivo imaging to
demonstrate that mouse T-ALL cells were
in close contact with CXCL12 producing
stroma. Because T-ALL cells themselves
did not produce CXCL12, they next
confirmed that the mouse T-ALL cells
were dependent on the production of
CXCL12 by vascular endothelial cells
(Figure 1A). In agreement with this, condi-
tional deletion of Cxcr4 in the mouseCancer CeT-ALL cells resulted in a strong reduction
of the total number of T-ALL cells and an
absence of infiltration of leukemia cells
in bone marrow, spleen, thymus, and
other organs. Moreover, Cxcr4 deletion
in the T-ALL cells led to prolonged survival
of the animals, even if Cxcr4 was deleted
after disease was established, suggesting
that CXCR4 inhibition could be a valuable
therapeutic strategy. To further support
the potential of CXCR4 inhibition, Pitt
et al. (2015) performed in vivo treatment
of two patient-derived T-ALL xenografts
using AMD3465, a selective CXCR4
antagonist. The treatment with AMD3465
significantly reducedT-ALLgrowth in vivo,
as observed by reduced numbers of
T-ALL cells in the blood, reduced spleno-
megaly, and a virtual absence of infiltra-
tion of T-ALL cells in lungs, liver, or brain
of the mice, confirming this as a bona
fide therapeutic strategy (Pitt et al., 2015).
In the second independent study pub-
lished in this issue, Passaro et al. (2015)
come to similar conclusions as they
continue to investigate their conditional
calcineurin knock-out mouse model.
Previous work by the group of Jacques
Ghysdael demonstrated that calcineurin,
a serine threonine phosphatase consist-
ing of one of the two catalytic subunits
(Ppp3ca and Ppp3cb) and one regulatory
subunit (Ppp3r1), is important for the
migration of T-ALL cells and essential
for the leukemia initiating properties of
T-ALL (Medyouf et al., 2007; Gachet
et al., 2013). They extend this work in
the current study, with Passaro et al.
(2015) linking these previous observations
with an effect on CXCR4 surface expres-
sion and the subsequent ability of the
leukemia cells to respond to CXCL2. The
mechanism by which calcineurin affects
CXCR4 trafficking is at least in partll 27, June 8, 2015 ª2015 Elsevier Inc. 745
Figure 1. CXCR4 Surface Expression Is Essential for T-ALL Leukemia Cell Maintenance
(A) T-ALL cells (which are CXCR4 positive) are in close contact to vascular cells in the bone marrow that produce CXCL12 (Pitt et al., 2015).
(B) CXCR4 cell surface expression is, in part, regulated by cortactin, and the expression of cortactin is dependent on calcineurin (Passaro et al., 2015).
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Previewscaused by effects on the expression of
cortactin, an actin-binding protein impli-
cated in the regulation of cytoskeleton
dynamics (Figure 1B). Passaro et al.
(2015) also confirmed that knock-down
of CXCR4 negatively affects T-ALL cell
migration and expansion in co-cultures
with stromal cells in vitro as well as
leukemia initiating cell potential in vivo.
The results of these two studies
highlight the essential role of the CXCL12/
CXCR4-driven interaction between T-ALL
propagating cells and the (vascular)
niche (Figure 1) and suggest that inhibi-
tors of the CXCL12/CXCR4 interaction
could have potential for the treatment of
T-ALL.746 Cancer Cell 27, June 8, 2015 ª2015 ElseREFERENCES
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